The introduction in 1998 of imatinib mesylate (IM) revolutionized management of patients
with chronic myeloid leukemia (CML) and the second generation of tyrosine kinase …

Next-generation sequencing (NGS) methods for cancer testing have been rapidly adopted
by clinical laboratories. To establish analytical validation best practice guidelines for NGS …

In recent years, the increasing awareness that somatic mutations and other genetic
aberrations drive human malignancies has led us within reach of personalized cancer …

Background A clinical trial that compared erlotinib with a placebo for non–small-cell lung
cancer demonstrated a survival benefit for erlotinib. We used tumor-biopsy samples from …

Abstract The AACR Project GENIE is an international data-sharing consortium focused on
generating an evidence base for precision cancer medicine by integrating clinical-grade …

Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute
of Canada Clinical Trials Group Study Page 1 Role of KRAS and EGFR As Biomarkers of …

A system in which immune-deficient mice are repopulated with cells from the human myeloid
lineage, and that provides an in vivo stem cell assay for human hematopoietic cells is …

An international basis for comparison of BCR-ABL mRNA levels is required for the common
interpretation of data derived from individual laboratories. This will aid clinical decisions for …

Purpose Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of
function mutations are common and appear to be important in the pathogenesis of …

MicroRNAs (miRs) are non-coding RNA molecules involved in cancer initiation and
progression. Deregulated miR expression has been implicated in cancer; however, there …